Shenhao started after the college entrance examination

Uriah first brought up the topic of Amgen Pharmaceuticals, and then added, "Amgen has been targeted recently, and various rumors against it and various negative public opinions have emerged in the market."

Andy from Merrill Lynch Investment Company took over, "I actually know this!"

The other four immediately looked at Andy, and Barton even asked, "What gossip is there?"

"Everyone should know that Amgen has a good relationship with that person, right?" Andy asked.

Barton nodded slightly, and the other three also nodded.

Richard of Berkshire Hathaway said affirmatively, "Amgen's Xia Guo representative is a guy with high emotional intelligence. He has a good relationship with that person, so Amgen can benefit from that person."

Richard added, "With the help of that person, the market value of the newly opened Amgen Industry Security Company of Williams 293 has risen sharply. Although it has not been officially listed, the valuation has exceeded 1 billion US dollars."

Andy responded affirmatively, "These are all secondary. The main thing is the cooperation project around rapamycin carried out by Amgen Anxin Life Sciences Group."

"Those giants in the same industry as Amgen are worried about the success of the rapamycin project, so they want to snipe Amgen in advance. The best is to dismember Amgen, and at worst, they have to find a way to block the cooperation of rapamycin." Andy added.

Andy continued to tease, "These guys will definitely fail!"

Richard seconded, "Although I don't know the details, I also think these guys will definitely fail."

Barton expressed a different opinion, "I think Amgen will be in deep trouble."

Andy denied, "What trouble can Amgen have?"

Andy continued, "That person is really good to Amgen. Not to mention the Guardian Robot, the second phase clinical trial quota of the Miracle Danshen Pill was only given to Amgen"

Francis asked with interest, "Does anyone know who the Amgen Xiaguo representative is?"

Uriah teased, "You Want to poach people? "

Andy responded, "Amgen's Xiaguo representative is Eric Waters, from San Diego, California. He was sent to Xiaguo in 2008 to serve as Amgen's Xiaguo representative."

Andy added, "If you want to poach people, I advise you to give up!"

Francis asked back, "Have you tried it?"

"Yes!" Andy did not deny, "We tried to poach people before Merrill Lynch invested, but the other party clearly refused."

"There is also an important news. Eric's family has successfully moved to Xiaguo and obtained Xiaguo's green card. Eric himself has also obtained a green card. He has not lived in Bald Eagle for a long time in the past four years." Andy added.

"It seems that the other party is determined to join Xiaguo?" Francis was a little surprised.

"It should be." Andy responded.

"Then we can't poach!" Uriah seconded.

Uriah added, "Perhaps we should acquire some Amgen shares. After all, if Amgen Anxin Life Sciences Group really overcomes the problems related to rapamycin, we will become Amgen shareholders and get first-hand information better."

Francis agreed, "I think it's okay!" (To read the novel, go to Faloo Novel Network!)

Others also agreed.

These geniuses in the financial field know very well what Amgen Pharmaceuticals is researching around rapamycin. If such research is really successful, let alone what economic benefits can be obtained, just obtaining related drugs through Amgen is very important.

"I suggest that we start buying Amgen shares today." Uriah suggested.

Uriah added, "It just so happens that the market is now in an uproar because of Anxin Investment and Xiaguo's sovereign fund. To borrow the old saying of Xiaguo, we can fish in troubled waters."

Francis nodded in agreement, "I agree!"[]

Andy naturally agreed and said, "Our Merrill Lynch Investment will follow!"

"Our Berkshire Hathaway will follow too." Richard seconded.

As for Barton of Morgan Investment Company?

Barton has a good relationship with Francis of BlackRock Capital Group. How could he refuse?

Uriah looked at everyone who agreed, and he added, "In order to avoid our companies competing with each other to push up Amgen's stock price, I have a suggestion."

The four looked at Uriah, waiting for Uriah to make a proposal.

"We will jointly operate this project. For example, Pioneer will operate it. We will acquire 5% of Amgen shares, and then the five of us will share it equally, each of us will get 1% of the shares, and the cost will be shared equally." Uriah proposed.

"If we acquire 5% of the shares and then acquire another 5% of the shares from the secondary market, if Andy and your Merrill Lynch don't want it, then the other four of us will share it equally." Uriah added.

"What do you think?" Uriah asked.

This approach shares the cost and shares the equity, thus reducing the possibility of competition.

In addition, everyone just wants to become a shareholder of Amgen to obtain the research progress of rapamycin and first-hand information, not for profit, so Uriah thinks the probability of cooperation is very high. .